Seguici su

Dossier n. 176/2009 [Abstract] Use of antibacterials and antimycotics in Emilia-Romagna hospitals. Report 2007

  • In Emilia-Romagna region a progressive increase of hospital systemic antibacterial consumption is observed in the period 2004 through 2007: the rate measured by DDD per 100 patient days shows a 16% increase, the rate per 100 admissions increases by 18%.
  • During 2007, the overall hospital use of systemic antibacterials in the region was 82 DDD/100 patient days, ranging between 58 e 95 according with the considered Local Health Authority. The observed variability among hospital trusts is not completely explained by differences in typology of wards and patients case-mix.
  • A preferential use of broad-spectrum antibacterials with a bigger impact on the spread of antimicrobial resistance is observed. The most prescribed groups are: penicillins associated to beta-lactamase inhibitors (34% of total consumption), fluoroquinolones (19%) and third-generation cephalosporins (13%).
  • Amoxicillin/clavulanate is the most prescribed among penicillins associated to beta-lactamase inhibitors (59% of the total intra-class consumption); ciprofloxacin accounts for 57% of fluoroquinolones use; ceftriaxone represents the 67% of third-generation cephalosporins consumption.
  • Considering the antibacterial consumption referred to three typologies of wards (general medicine, geriatric and long-term care units) which result of leading interest from an epidemiologic point of view, the geriatric units show the most homogeneous pattern of prescription while the long-term care units have the lowest consumption rates.
  • The hospital use of systemic antimycotics mainly involves four typology of wards (haematology, oncology, intensive care and infectious disease units) and shows a lower degree of variability than antibacterials. The overall systemic antimycotic consumption observed in the region during 2007 is 4,5 DDD/100 patient days and the prescribed agents belong, in most case, to two different groups: triazole derivatives (86% of total consumption) and amphotericin B (12%).


Data di pubblicazione:
Scarica la pubblicazione:
download (PDF, 0.31 MB)

Azioni sul documento

pubblicato il 2009/03/01 01:00:00 GMT+2 ultima modifica 2019-01-17T19:08:33+02:00

Valuta il sito

Non hai trovato quello che cerchi ?

Piè di pagina